Results 221 to 230 of about 3,042,168 (283)

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

open access: yesBrain and Behavior, Volume 16, Issue 9, September 2026.
Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, driven by abnormal signaling pathways that promote growth and resistance to treatment. Conventional therapies are inadequate, highlighting the need for novel multitargeted approaches.
Mehrukh Zehravi   +13 more
wiley   +1 more source

Protective Effect of Phytic Acid in Cardiovascular Diseases: A Systematic Review

open access: yesChemFoodChem, Volume 2, Issue 3, September 2026.
ABSTRACT Cardiovascular diseases (CVDs) are a cluster of ailments that impact the heart and blood vessels and are a primary public health problem of mortality on a global scale. Phytic acid, a dietary constituent frequently present in foods like seeds, has been linked to many pharmacological attributes, including anti‐cancer, antioxidant, anti ...
Marta M. S. de Freitas Almeida   +7 more
wiley   +1 more source

Proteo-Metabolomic Profiling of PMM2-CDG Reveals Dysregulation of Retinoic Acid Synthesis, Myo-Inositol, and the Hexosamine Pathway. [PDF]

open access: yesJ Inherit Metab Dis
Gallego D   +10 more
europepmc   +1 more source

Comprehensive In Silico Analysis Identifies MSTO1 and LIG1 as Candidate Biomarkers With Diagnostic and Prognostic Relevance in Hepatocellular Carcinoma

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and remains a major cause of cancer‐related mortality worldwide. Its poor clinical outcomes are largely attributed to late‐stage diagnosis and the limited accuracy of currently available diagnostic and prognostic biomarkers.
Jana Hamad   +2 more
wiley   +1 more source

Recent Advancements in Drug Delivery Across the Blood–Brain Barrier in Amyotrophic Lateral Sclerosis (ALS)

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Progressive BBB/BSCB dysfunction is increasingly recognized as both a pathological feature and a therapeutic barrier in ALS. Novel delivery technologies and barrier‐restoration strategies may enhance CNS drug exposure, improve the efficacy of disease‐modifying therapies, and advance ALS treatment. ABSTRACT Background Amyotrophic lateral sclerosis (ALS)
Nitesh Sanghai   +9 more
wiley   +1 more source

Fatty Acid‐Binding Protein 5 Potentially Regulates the Proliferation and Metastasis of Uveal Melanoma Cells Through the PI3K/AKT/mTOR Signaling Pathway

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Single‐cell and bulk sequencing reveal SPON2, MATK, and FABP5 as prognostic indicators in uveal melanoma. We demonstrated that FABP5 promotes malignancy via the PI3K/AKT/mTOR pathway, as genetic knockdown impairs tumor growth and is rescued by 740Y‐P pharmacological pathway activation. These findings highlight FABP5 maybe as a critical driver of immune
Yue Du   +4 more
wiley   +1 more source

Barrier Function and Biophysical Effects of 0.104% and 0.247% Retinol Creams in Mature Facial Skin: A Prospective Study. [PDF]

open access: yesInt J Mol Sci
Pordąb I   +10 more
europepmc   +1 more source

Molecular genetics of meiotic initiation in mammals. [PDF]

open access: yesBiol Reprod
Wenner SM   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy